New developments in the treatment of postmenopausal breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/74875
Title:
New developments in the treatment of postmenopausal breast cancer.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
In recent years, new agents have challenged tamoxifen as the standard endocrine therapy for postmenopausal breast cancer. This article reviews developments with regard to the third-generation aromatase inhibitors (AIs)--anastrozole, letrozole and exemestane--and fulvestrant, the first of a new type of estrogen receptor antagonist that, unlike tamoxifen, has no partial agonist activity. The final results of the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial, at a median follow-up of more than five years, and recent results from switching studies with anastrozole and exemestane, strengthen the position of these AIs as adjuvant treatment for hormone receptor-positive early breast cancer. Sequencing options for the future are also discussed because non-steroidal AIs are increasingly used early in the treatment sequence.
Affiliation:
CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
New developments in the treatment of postmenopausal breast cancer. 2005, 16 (9):420-8 Trends Endocrinol. Metab.
Journal:
Trends in Endocrinology and Metabolism
Issue Date:
Nov-2005
URI:
http://hdl.handle.net/10541/74875
DOI:
10.1016/j.tem.2005.09.003
PubMed ID:
16213745
Type:
Article
Language:
en
ISSN:
1043-2760
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-07-22T08:43:11Z-
dc.date.available2009-07-22T08:43:11Z-
dc.date.issued2005-11-
dc.identifier.citationNew developments in the treatment of postmenopausal breast cancer. 2005, 16 (9):420-8 Trends Endocrinol. Metab.en
dc.identifier.issn1043-2760-
dc.identifier.pmid16213745-
dc.identifier.doi10.1016/j.tem.2005.09.003-
dc.identifier.urihttp://hdl.handle.net/10541/74875-
dc.description.abstractIn recent years, new agents have challenged tamoxifen as the standard endocrine therapy for postmenopausal breast cancer. This article reviews developments with regard to the third-generation aromatase inhibitors (AIs)--anastrozole, letrozole and exemestane--and fulvestrant, the first of a new type of estrogen receptor antagonist that, unlike tamoxifen, has no partial agonist activity. The final results of the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial, at a median follow-up of more than five years, and recent results from switching studies with anastrozole and exemestane, strengthen the position of these AIs as adjuvant treatment for hormone receptor-positive early breast cancer. Sequencing options for the future are also discussed because non-steroidal AIs are increasingly used early in the treatment sequence.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBreast Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshTamoxifen-
dc.subject.meshTriazoles-
dc.titleNew developments in the treatment of postmenopausal breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalTrends in Endocrinology and Metabolismen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.